21 CFR Part 58 · Good Laboratory Practice for Nonclinical Laboratory Studies

§ 58.105 Test and control article characterization

Subpart F - Test and Control Articles Official text on eCFR Amendment history

(a) The identity, strength, purity, and composition or other characteristics which will appropriately define the test or control article shall be determined for each batch and shall be documented. Methods of synthesis, fabrication, or derivation of the test and control articles shall be documented by the sponsor or the testing facility. In those cases where marketed products are used as control articles, such products will be characterized by their labeling.

(b) The stability of each test or control article shall be determined by the testing facility or by the sponsor either:

(1) Before study initiation, or

(2) concomitantly according to written standard operating procedures, which provide for periodic analysis of each batch.

(c) Each storage container for a test or control article shall be labeled by name, chemical abstract number or code number, batch number, expiration date, if any, and, where appropriate, storage conditions necessary to maintain the identity, strength, purity, and composition of the test or control article. Storage containers shall be assigned to a particular test article for the duration of the study.

(d) For studies of more than 4 weeks' duration, reserve samples from each batch of test and control articles shall be retained for the period of time provided by § 58.195 .

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 58.105

Form FDA 483 observations citing this section, fiscal years 2011–2011 (Bioresearch Monitoring).

  • Test article: characterization 1

Warning letters citing § 58.105

1 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 58.105

Amendment history

Federal Register documents that created or amended this section.